The peptide library
What each compound is, what the evidence in people shows, and what taking it looks like week to week. In plain words, with every number from its source.
The GLP-1 family
- SemaglutideOne receptor, several brand names, and two very different ways to take it.Approved by the FDA, as a weekly injection and a daily pill.
- TirzepatideTwo hormone receptors instead of one.Approved by the FDA, as a weekly injection.
- RetatrutideThree receptors, and the third works in a different way.Not approved by the FDA, and in phase 3 trials as of October 2026.
Growth-hormone peptides
- SermorelinOnce an FDA-approved drug, as Geref, now discontinued.Was FDA-approved, as Geref, until the approval was withdrawn in 2009.
- CJC-1295 (no DAC)The form without DAC, one of two different drugs that share the name CJC-1295.Not approved by the FDA.
- CJC-1295 with DACThe same peptide with an add-on that keeps it in the blood for days.Not approved by the FDA.
- IpamorelinPrompts growth-hormone release like its neighbours, through a different receptor.Not approved by the FDA.
- TesamorelinRaises growth hormone, and has a current FDA label.Approved by the FDA, as Egrifta.
Repair and recovery peptides
- BPC-157Based on a protein in stomach juice. Most of the evidence for it comes from animal and cell studies.Not approved by the FDA.
- TB-500A small piece of a protein, easily mistaken for the whole thing.Not approved by the FDA.
- GHK-CuA copper-carrying peptide with two routes, on the skin and by injection, and separate evidence for each.Not approved by the FDA as a drug.
- KPVThree amino acids from the tail end of a larger hormone.Not approved by the FDA.
Mitochondrial and metabolic compounds
- MOTS-cA peptide whose gene sits in your mitochondria, not in the cell nucleus.Not approved by the FDA.
- NAD+It's involved in how cells make energy. Here it's injected, and that changes the question.No injected NAD+ product is approved by the FDA.
Melanocortin peptides
- PT-141 (Bremelanotide)An approved drug, with one fixed dose on its label.Approved by the FDA, as Vyleesi.
- Melanotan IIA tanning peptide that isn't FDA-approved, with case reports of moles changing quickly or in worrying ways.Not approved by the FDA.
- AfamelanotideAn approved implant that darkens skin, for a condition that makes sunlight painful.Approved by the FDA, as Scenesse, an implant placed by a clinician.
- SetmelanotideAn approved daily injection for obesity caused by an underactive hunger pathway in the brain, not for obesity in general.Approved by the FDA in 2020, as Imcivree, for obesity caused by certain genetic conditions; acquired hypothalamic obesity was added in March 2026.
Cognition peptides
- SemaxA short peptide built on a piece of a stress hormone, with doses in its registered instructions but thin evidence as a nootropic, for memory and focus.Registered as a medicine in Russia, where it's dispensed only on prescription; not approved by the FDA.
- SelankAn anxiety medicine registered in Russia, discussed for memory and focus.Registered as a medicine in Russia, where it's dispensed without a prescription; not approved by the FDA.
Sleep peptides
More GLP-1 drugs
- LiraglutideA once-a-day GLP-1 shot, sold as Victoza for type 2 diabetes and as Saxenda for weight management.Approved by the FDA in 2010 for type 2 diabetes, as Victoza, and in 2014 for weight management, as Saxenda; generic versions of both are approved.
- DulaglutideA once-a-week GLP-1 shot, built by joining a GLP-1-like chain to part of an antibody.Approved by the FDA in 2014 for type 2 diabetes, as Trulicity.
- ExenatideA GLP-1 drug originally found in the venom of the Gila monster, a lizard.Approved by the FDA in 2005 for type 2 diabetes, as Byetta, and now listed by the FDA as discontinued, along with every form of Bydureon and the one generic version of Byetta.
- LixisenatideA once-a-day GLP-1 that, in the US, now comes only mixed with insulin, as Soliqua.Approved by the FDA in 2016 for type 2 diabetes, as Adlyxin and as part of Soliqua; the FDA now lists Adlyxin as discontinued, so in the US it comes only in Soliqua.
- AlbiglutideA weekly GLP-1 shot that its maker stopped selling worldwide, saying the reasons were commercial.Approved by the FDA in 2014 for type 2 diabetes, as Tanzeum, and now listed by the FDA as discontinued.
- OrforglipronA GLP-1 pill that isn't a peptide, approved in the US as Foundayo.Approved by the FDA in 2026 for long-term weight management, as Foundayo.
- EfpeglenatideA GLP-1 shot based on a peptide first found in Gila monster venom, approved in South Korea.Approved in South Korea in October 2026 for weight management in adults without diabetes; not approved by the FDA.
GLP-1 and glucagon drugs
- MazdutideA weekly shot acting on GLP-1 and glucagon, approved in China.Approved in China in 2025, for weight management and for type 2 diabetes; not approved by the FDA.
- SurvodutideA weekly shot acting on glucagon and GLP-1, tested for weight and for fatty liver disease.Not approved by the FDA, and in phase 3 trials as of October 2026.
- PemvidutideA GLP-1 and glucagon shot, now in trials for liver disease and alcohol use disorder.Not approved by the FDA, and in a phase 3 trial for MASH as of October 2026.
Amylin drugs
- PramlintideSymlin: a lab-made version of amylin, the hormone released with insulin, injected before each major meal.Approved by the FDA in 2005 for diabetes alongside mealtime insulin, as Symlin, and now listed by the FDA as discontinued.
- CagrilintideA long-acting version of amylin, tested as a once-a-week injection.Not approved by the FDA, and in phase 3 trials on its own as of October 2026.
- CagriSemaSemaglutide, the drug in Wegovy and Ozempic, paired with an amylin drug in one weekly injection.Not approved by the FDA as of October 2026; Novo Nordisk filed for approval in December 2025.
- AmycretinOne molecule that acts on both GLP-1 and amylin receptors, now also called zenagamtide.Not approved by the FDA, and in phase 3 trials as of October 2026.
- PetrelintideAn amylin drug built on human amylin and tested as a weekly injection.Not approved by the FDA, and in phase 3 trials as of October 2026.
Growth-hormone fragments
- AOD-9604A piece of growth hormone, tested in people as an obesity drug and dropped when a larger trial found no significant difference in weight loss from placebo.Not approved by the FDA, and in December 2024 an FDA advisory committee voted against adding it to the list of ingredients that state-licensed pharmacies may use to compound drugs.
- Fragment 176-191A name for a piece of growth hormone: some sources use it for AOD-9604, and a lab that tests athletes for banned drugs treats it as a separate substance.Not approved by the FDA: no approved drug contains AOD-9604, the molecule this name is sometimes used for.
Not peptides, but sold beside them
Topics
Get an early invite to Tidepath
The app isn't in the App Store yet. Leave your email for an early invite, and tips for your first month.
Get an early invite, tips and occasional news from Tidepath. Unsubscribe anytime. Privacy · Health data privacy · Sender and contact details